Is Vertex Pharmaceuticals' Monopoly in Danger?
Over the past decade, Vertex Pharmaceuticals (NASDAQ: VRTX) has delivered above-average returns. The secret behind the biotech's success isn't much of a secret. The drugmaker developed and marketed medicines -- the only ones in the world -- that target the underlying causes of a rare disease called cystic fibrosis (CF).
So far, Vertex's monopoly has remained intact despite many of its peers trying to break into this space. But could that change soon? Sionna Therapeutics, a privately held biotech, certainly hopes so.
Source Fool.com
Vertex Pharmaceuticals Inc. Stock
The stock is one of the favorites of our community with 59 Buy predictions and 2 Sell predictions.
With a target price of 450 € there is a slightly positive potential of 5.1% for Vertex Pharmaceuticals Inc. compared to the current price of 428.15 €.